Anpheros Search · Treatment

Duloxetine

Also known as: Yentreve · Cymbalta · Duloxetine Lilly · Duloxetine Viatris (previously Duloxetine Mylan) · Duloxetine Zentiva · DULOXETINE HYDROCHLORIDE

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, duloxetine is indicated in adults for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, and generalised anxiety disorder. Also in the European Union, it is indicated for women for the treatment of moderate to severe stress urinary incontinence. In the United States, duloxetine is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder in adults, generalized anxiety disorder in adults and pediatric patients 7 years of age and older, and diabetic peripheral neuropathic pain in adults. Additionally, in the United States, it is indicated for the treatment of fibromyalgia in adults and pediatric patients 13 years of age and older, as well as chronic musculoskeletal pain in adults.

From: Source: European Medicines Agency (EMA), Cymbalta — EPAR, 09/07/2024. © European Medicines Agency. · Source: European Medicines Agency (EMA), Duloxetine Lilly — EPAR, 09/07/2024. © European Medicines Agency. · Source: European Medicines Agency (EMA), Yentreve — EPAR, 09/07/2024. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm: 72625 duloxetine
EMA: EMEA/H/C/000545, EMEA/H/C/000572, EMEA/H/C/004000, EMEA/H/C/003981, EMEA/H/C/003935

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Cymbalta

Treatment of major depressive disorder. Treatment of diabetic peripheral neuropathic pain. Treatment of generalised anxiety disorder. Cymbalta is indicated in adults.

Source: European Medicines Agency (EMA), Cymbalta — EPAR, 09/07/2024. © European Medicines Agency.

Document date: 09/07/2024 · Official document →

FDA (USA) Duloxetine

1 INDICATIONS AND USAGE Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults and pediatric patients 13 years of age and older ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) Duloxetine delayed-release capsules are indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults and pediatric patients 13 years of age and older Chronic musculoskeletal pain in adults

Data provided by the U.S. Food and Drug Administration.

Document date: 20260710 · Official document →

EMA (EU) Duloxetine Lilly

Duloxetine Lilly is indicated in adults for: Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Lilly is indicated in adults.

Source: European Medicines Agency (EMA), Duloxetine Lilly — EPAR, 09/07/2024. © European Medicines Agency.

Document date: 09/07/2024 · Official document →

EMA (EU) Yentreve

Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).

Source: European Medicines Agency (EMA), Yentreve — EPAR, 09/07/2024. © European Medicines Agency.

Document date: 09/07/2024 · Official document →

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Duloxetine approved for in the European Union?

Treatment of major depressive disorder. Treatment of diabetic peripheral neuropathic pain. Treatment of generalised anxiety disorder. Cymbalta is indicated in adults. (Source: European Medicines Agency (EMA), Cymbalta — EPAR, 09/07/2024. © European Medicines Agency.)

Sources and attribution

Data provided by the U.S. Food and Drug Administration.
Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →

About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.

Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.

What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.

Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.

In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.